1,616
Views
12
CrossRef citations to date
0
Altmetric
Original Articles

MDMA and the “Ecstasy Paradigm”

, Ph.D.

REFERENCES

  • American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association.
  • Aronson, J.; Fried, C.B. & Good, C. 2002. Reducing the effects of stereotype threat on African American college students by shaping theories of intelligence. Journal of Experimental Social Psychology 38: 113–25.
  • Baumann, M.H.; Wang, X. & Rothman, R.B. 2007. 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: A reappraisal of past and present findings. Psychopharmacology 189: 407–24.
  • Bhattachary, S. & Powell, J.H. 2001. Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or “ecstasy”: Evidence for cognitive impairment. Psychological Medicine 31: 47–58.
  • Blier, P. 2008. Resiliency of monoaminergic systems: The 80% rule and its relevance to drug development. Journal of Psychopharmacology 22: 587–9.
  • Bond, A.J.; Verheyden, S.L.; Wingrove, J. & Curran, H.V. 2004. Angry cognitive bias, trait aggression and impulsivity in substance users. Psychopharmacology 171: 331–9.
  • Boot, B.P.; Mechan, A.O.; McCann, U.D. & Ricaurte, G.A. 2002. MDMA- and p-chlorophenylalanine-induced reduction in 5-HT concentrations: Effects on serotonin transporter densities. European Journal of Pharmacology 453: 239–44.
  • Boys, A.; Marsden, J.; Griffiths, P.; Fountain, J.; Stillwell, G. & Strang, J. 1999. Substance use among young people: The relationship between perceived functions and intentions. Addiction 94: 1043–50.
  • Boys, A.; Marsden, J. & Strang, J. 2001. Understanding reasons for drug use amongst young people: A functional perspective. Health Education Research 16: 457–69.
  • Butler, G.K.L. & Montgomery, A.M.J. 2004. Impulsivity, risk taking and recreational “ecstasy” (MDMA) use. Drug and Alcohol Dependence 76: 55–62.
  • Cole, J.C.; Bailey, M.; Sumnall, H.R.; Wagstaff, G.F. & King, L.A. 2002. The content of ecstasy tablets: Implications for the study of their long-term effects. Addiction 97: 1531–6.
  • Cole, J.C.; Michailidou, K.; Jerome, L. & Sumnall, H.R. 2006. The effects of stereotype threat on cognitive function in ecstasy users. Journal of Psychopharmacology 20: 518–25.
  • Cole, J.C. & Sumnall, H.R. 2003a. Altered states: The clinical effects of ecstasy. Pharmacology and Therapeutics 98: 35–58.
  • Cole, J.C. & Sumnall, H.R. 2003b. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neuroscience and Biobehavioral Reviews 27: 99–217.
  • Cole, J.; Sumnall, H. & Grob, C. 2002. Sorted: Ecstasy facts and fiction. The Psychologist 15: 464–74.
  • Cole, J.C.; Sumnall, H.R.; Smith, G.W. & Rostami-Hodjegan, A. 2005. Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs. Journal of Psychopharmacology 19: 63–6.
  • Cole, J.C.; Sumnall, H.R. & Wagstaff, G.F. 2002a. Methodological problems with ecstasy and the SCL-90. Psychopharmacology 162: 215–17.
  • Cole, J.C.; Sumnall, H.R. & Wagstaff, G.F. 2002b. What is a dose of ecstasy? Journal of Psychopharmacology 16: 189–91.
  • Croft, R.J.; Klugman, A.; Baldeweg, T. & Gruzelier, J.H. 2001. Electrophysiological evidence of serotonergic impairment in long-term MDMA (“ecstasy”) users. American Journal of Psychiatry 158: 1687–92.
  • Curran, H.V. 2000. Is MDMA (“ecstasy”) neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology 42: 34–41.
  • Curran, H.V. & Robjant, K. 2006. Eating attitudes, weight concerns and beliefs about drug effects in women who use ecstasy. Journal of Psychopharmacology 20: 425–31.
  • Curran, H.V. & Verheyden, S.L. 2003. Altered response to tryptophan supplementation after long-term abstention from MDMA (ecstasy) is highly correlated with human memory function. Psychopharmacology 169: 91–103.
  • Davison, D. & Parrott, A.C. 1997. Ecstasy (MDMA) in recreational users: Self-reported psychological and physiological effects. Human Psychopharmacology 12: 221–26.
  • de la Torre, R. & Farré, M. 2004. Neurotoxicity of MDMA (ecstasy): The limitations of scaling from animals to humans. Trends in Pharmacological Sciences 25: 505–8.
  • de la Torre, R.; Farré, M.; Ortuño, J.; Mas, M.; Brenneisen, R.; Roset, P.N.; Segura, J. & Camí, J. 2000. Non-linear pharmacokinetics of MDMA (“ecstasy”) in humans. British Journal of Clinical Pharmacology 49: 104–9.
  • Ditton, J.; Cooper, G.A.A.; Scott, K.S.; Allen, D.L.; Oliver, J.S. & Smith, I.D. 2000. Hair testing for “ecstasy” (MDMA) in volunteer Scottish drug users. Addiction Biology 5: 207–13.
  • European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2003. The State of the Drugs Problem in the European Union and Norway, Annual Report 2003. Lisbon: Office for Official Publications of the European Communities.
  • Fantegrossi, W.E.; Woolverton, W.L.; Kilbourn, M.; Sherman, P.; Yuan, J.; Hatzidimitriou, G.; Ricaurte, G.A.; Woods, J.H. & Winger, G. 2004. Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology 29: 1270–81.
  • Fisk, J.E.; Montgomery, C.; Murphy, P. & Wareing, M. 2004. Evidence for executive deficits among users of MDMA (ecstasy). British Journal of Psychology 95: 457–66.
  • Forensic Science Service. 2006. Email message to author, May.
  • Forsyth, A.J.M. 1996. Places and patterns of drug use in the Scottish dance scene. Addiction 91: 511–21.
  • Fox, H.C.; Parrott, A.C. & Turner, J.J.D. 2001a. Ecstasy use: Cognitive deficits related to dosage rather than self-reported problematic use of the drug. Journal of Psychopharmacology 15: 273–81.
  • Fox, H.C.; Toplis, A.S.; Turner, J.J.D. & Parrott, A.C. 2001b. Auditory verbal learning in drug-free ecstasy polydrug users. Human Psychopharmacology 16: 613–8.
  • Gamma, A.; Buck, A.; Berthold, T.; Liechti, M.E. & Vollenweider, F.X. 2000. 3,4-methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H215O]-PET in healthy humans. Neuropsychopharmacology 23: 388–95.
  • Gamma, A.; Jerome, L.; Liechti, M.E. & Sumnall, H.R. 2005. Is ecstasy perceived to be safe? A critical survey. Drug and Alcohol Dependence 77: 185–93.
  • Hammersley, R.; Ditton, J.; Smith, I. & Short, E. 1999. Patterns of ecstasy use by drug users. British Journal of Criminology 39: 625–47.
  • Hansen, D.; Maycock, B. & Lower, T. 2001. “Weddings, parties, anything …,” a qualitative analysis of ecstasy use in Perth, Western Australia. International Journal of Drug Policy 12: 181–99.
  • Heffernan, T.M.; Jarvis, H.; Rodgers, J.; Scholey, A.B. & Ling, J. 2001. Prospective memory, everyday cognitive failure and central executive function in recreational users of ecstasy. Human Psychopharmacology 16: 607–12.
  • Heffernan, T.M.; Ling, J. & Scholey, A.B. 2002. Subjective ratings of prospective memory deficits in MDMA (“ecstasy”) users. Human Psychopharmacology 16: 339–44.
  • Hoshi, R.; Mullins, K.; Boundy, C.; Brignell, C.; Piccini, P. & Curran, H.V. 2007. Neurocognitive function in current and ex-users of ecstasy in comparison to both matched polydrug-using controls and drug-naive controls. Psychopharmacology 194: 371–9.
  • Hoshi, R.; Pratt, H.; Mehta, S.; Bond, A.J. & Curran, H.V. 2006. An investigation into the sub-acute effects of ecstasy on aggressive interpretative bias and aggressive mood: Are there gender differences? Journal of Psychopharmacology 20: 291–301.
  • Huxster, J.K.; Pirona, A. & Morgan, M.J. 2006. The sub-acute effects of recreational ecstasy (MDMA) use: A controlled study in humans. Journal of Psychopharmacology 20: 281–90.
  • Kish, S.J. 2002. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacology, Biochemistry and Behavior 71: 845–55.
  • Kouimtsidis, C.; Schifano, F.; Sharp, T.; Ford, L. & Magee, C. 2006. Neurological and psychopathological sequelae associated with a lifetime intake of 40,000 ecstasy tablets. Psychosomatics 47: 86–7.
  • Lloyd, K.; Brown, C. & Emmens, T. 2002. Patterns of Ecstasy Use in Devon and Cornwall. Exeter: The Mental Health Research Group, Peninsula Medical School.
  • Lora-Tamayo, C.; Tena, T.; Rodríguez, A.; Moreno, D.; Sancho, J.R.; Enseñat, P. & Muela, F. 2004. The designer drug situation in Ibiza. Forensic Science International 140: 195–206.
  • Luus, C.A.E. & Wells, G.L. 1994. The malleability of eyewitness confidence: Co-witness and perseverance effects. Journal of Applied Psychology 79: 714–23.
  • MacInnes, N.; Handley, S.L. & Harding G.F.A. 2001. Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. Journal of Psychopharmacology 15: 181–6.
  • McCann, U.D. & Ricaurte, G.A. 2001. Caveat emptor: Editors beware. Neuropsychopharmacology 24: 333–4.
  • McElrath, K. & McEvoy, K. 2002. Negative experiences on ecstasy: The role of drug, set and setting. Journal of Psychoactive Drugs 34: 199–208.
  • Milroy, C.M.; Clark, J.C. & Forrest, A.R.W. 1996. Pathology of deaths associated with “ecstasy” and “eve” misuse. Journal of Clinical Pathology 49: 9–53.
  • Montgomery, C.; Fisk, J.E. & Newcombe, R. 2005a. The nature of ecstasy-group related deficits in associative learning. Psychopharmacology 180: 141–9.
  • Montgomery, C.; Fisk, J.E.; Newcombe, R. & Murphy, P.N. 2005b. The differential effects of ecstasy/polydrug use on executive components: Shifting, inhibition, updating and access to semantic memory. Psychopharmacology 182: 262–76.
  • Morgan, M.J. 1998. Recreational use of “ecstasy” (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 19: 252–64.
  • Morgan, M.J.; McFie, L.; Fleetwood, L.H. & Robinson, J.A. 2002. Ecstasy (MDMA): Are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology 159: 294–303.
  • Munafò, M.R.; Attwood, A.S. & Flint, J. 2008. Bias in genetic association studies: Effects of research location and resources. Psychological Medicine 38: 1213–4.
  • Page, R.A. & Handley, G.W. 1993. The effect of preventative measures in reducing after effects to hypnosis. American Journal of Clinical Hypnosis 36: 26–37.
  • Parrott, A.C. 2005. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or ecstasy. Journal of Psychopharmacology 19: 71–83.
  • Parrott, A.C. & Lasky, J. 1998. Ecstasy (MDMA) effects upon mood and cognition: Before, during and after a Saturday night dance. Psychopharmacology 139: 261–8.
  • Rainville, P.; Duncan, G.H.; Price, D.D.; Carrier, B. & Bushnell, M.C. 1997. Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science 277: 968–71.
  • Ramsey, J.D.; Butcher, M.A.; Murphy, M.F.; Lee, T.; Johnston, A. & Holt, D.W. 2001. A new method to monitor drugs at dance venues. British Medical Journal 323: 603.
  • Reay, J.L.; Hamilton, C.; Kennedy, D.O. & Scholey, A.B. 2006. MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes. Journal of Psychopharmacology 20: 385–8.
  • Reilley, R.R. & Rodolfa, E.R. 1981. Concentration, attention and hypnosis. Psychological Reports 48: 811–4.
  • Ricaurte, G.A.; Yuan, J.; Hatzdimitriou, G.; Cord, B.J. & McCann, U.D. 2002. Severe dopaminergic neurotoxicity in primates after a single recreational dose regimen of MDMA (“ecstasy”). Science 297: 2260–3.
  • Saunders, N. 1997. Ecstasy Reconsidered. London: Saunders.
  • Scholey, A.B.; Parrott, A.C.; Buchanan, T.; Heffernan, T.M.; Ling, J. & Rodgers R.J. 2004. Increased intensity of ecstasy and polydrug usage in the more experienced recreational ecstasy/MDMA users: A WWW study. Addictive Behaviors 29: 743–52.
  • Semple, D.M.; Ebmeier, K.P.; Glabus, M.F.; O’Carroll, R.E. & Johnstone, E.C. 1999. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (“ecstasy”) users. British Journal of Psychiatry 175: 63–9.
  • Sherlock, K.; Wolff, K.; Hay, A.W.M. & Conner, M. 1999. Analysis of illicit ecstasy tablets: Implications for clinical management in the accident and emergency department. Journal of Accident and Emergency Medicine 16: 194–7.
  • Spanos, N.P. 1989. Experimental research on hypnotic analgesia. In: N.P. Spanos & J.F. Chaves (Eds.) Hypnosis: The Cognitive-Behavioral Perspective. New York: Prometheus.
  • Spanos, N.P.; Jones, B. & Malfara, A. 1982. Hypnotic deafness: Now you hear it—now you still hear it. Journal of Abnormal Psychology 90: 75–7.
  • Steele, C.M. & Aronson, J. 1995. Stereotype threat and the intellectual test performance of African Americans. Journal of Personality and Social Psychology 69: 797–811.
  • Sumnall, H.R. & Cole, J.C. 2005. Self-reported depressive symptomatology in community samples of polysubstance misusers who report ecstasy use: A meta-analysis. Journal of Psychopharmacology 19: 84–92.
  • Sumnall, H.R.; Cole, J.C. & Jerome, L. 2006. The varieties of ecstatic experience: An exploration of the subjective experiences of ecstasy. Journal of Psychopharmacology 20: 670–82.
  • Sumnall, H.R.; Tyler, E.; Wagstaff, G.F. & Cole, J.C. 2004a. A behavioural economic analysis of alcohol, amphetamine, cocaine, and ecstasy purchases by polysubstance misusers. Drug and Alcohol Dependence 76: 93–9.
  • Sumnall, H.R.; Wagstaff, G.F. & Cole, J.C. 2004b. Self-reported psychopathology in polydrug users. Journal of Psychopharmacology 18: 63–9.
  • Tarter, R.E.; Kirisci, L.; Habeych, M.; Reynolds, M. & Vanyukov, M. 2004. Neurobehavior disinhibition in childhood predisposes boys to substance use disorder by young adulthood: Direct and mediated etiologic pathways. Drug and Alcohol Dependence 73: 121–32.
  • Tarter, R.E.; Kirisci, L.; Mezzich, A.; Cornelius, J.R.; Pajer, K.; Vanyukov, M.; Gardner, W.; Blackson, T. & Clark, D. 2003. Neurobehavioral disinhibition in childhood predicts early age at onset of substance use disorder. American Journal of Psychiatry 160: 1078–85.
  • Thomasius, R.; Petersen, K.; Buchert, R.; Andresen, B.; Zapletalova, P.; Wartberg, L.; Nebeling, B. & Schmoldt, A. 2003. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 167: 85–96.
  • van de Wijngaart, G.; Braam, R.; de Bruin, D.; Fris, M.; Maalsté, N.J.M. & Verbraeck, H.T. 1999. Ecstasy use at large-scale dance events in the Netherlands. Journal of Drug Issues 29: 679–702.
  • Verheyden, S.L.; Hadfield, J.; Calin, T. & Curran, H.V. 2002. Sub-acute effects of MDMA (+3,4-methylenedioxymethamphetamine, “ecstasy”) on mood: Evidence of gender differences. Psychopharmacology 161: 23–31.
  • Verheyden, S.L.; Henry, J.A. & Curran, H.V. 2003. Acute, sub-acute and long-term subjective consequences of “ecstasy” (MDMA) consumption in 430 regular users. Human Psychopharmacology 18: 507–17.
  • Wareing, M.; Fisk, J.E. & Murphy, P.N. 2000. Working memory deficits in current and previous users of MDMA (“ecstasy”). British Journal of Psychology 91: 181–8.
  • Winstock, A.R.; Griffiths, P. & Stewart, D. 2001. Drugs and the dance music scene: A survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug and Alcohol Dependence 64: 9–17.
  • Wolff, K.; Hay, A.W.M.; Sherlock, K. & Conner, M. 1995. Contents of “ecstasy”. Lancet 346: 1100–1.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.